Form 4: Teva Pharmaceutical Industries Director Ronit Satchi-Fainaro Acquires Restricted Share Units

Director Ronit Satchi-Fainaro acquired 9,632 restricted share units of Teva Pharmaceutical Industries on June 6, 2024, which vest on June 6, 2025.

Summary

• On June 6, 2024, Ronit Satchi-Fainaro, a director of Teva Pharmaceutical Industries Ltd., acquired 9,632 restricted share units.
• These restricted share units vest on June 6, 2025.
• Each restricted share unit represents a contingent right to receive one ordinary share or the cash value of one ordinary share, at the discretion of the Human Resources and Compensation Committee.
• The ordinary shares may be represented by American Depositary Shares (ADS), where each ADS currently represents one ordinary share.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of an insider transaction. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their holdings in the company's stock.

Stakeholder Impact

• The acquisition of restricted share units by a director aligns the director's interests with those of the shareholders, as the value of the units is tied to the company's stock performance.

Key Dates